The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review

Dolan, R. D. , Laird, B., Horgan, P. G. and McMillan, D. C. (2018) The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: A systematic review. Critical Reviews in Oncology/Hematology, 132, pp. 130-137. (doi:10.1016/j.critrevonc.2018.09.016)

[img] Text
170307.pdf - Accepted Version
Restricted to Repository staff only until 4 October 2020.

342kB

Abstract

Background: The prognostic value of the systemic inflammatory response in cancer has been well established in observational studies. This review aims to examine and rationalise the evidence for the role of systemic inflammation based prognostic scores in randomised clinical trials. Method: An extensive literature review using targeted medical subject headings was carried out in the MEDLINE, EMBASE, and CDSR databases until January 2018. Titles were examined for relevance and after exclusions bibliographies were hand searched to identify additional trials. Results: There were 29 trials containing data on 37,020 patients presented in full paper form and 8 trials containing data on 3805 patients presented in abstract form. Most trials were published within the last three years. Seven trials containing data on 6044 patients were published in 2015. Eight trials containing data on 4384 patients were published in 2016. Twelve trials containing data on 27,228 patients were published in 2017. The majority of trials were in advanced inoperable cancer and colorectal cancer was the most common cancer type with 11 articles containing data on 27,909 patients. The GPS/mGPS was shown to have prognostic value in randomised clinical trials in NSCLC, oesophageal cancer, pancreatic cancer, prostate cancer and breast cancer. The NLR/dNLR was shown to have prognostic value in randomised clinical trials in nasopharyngeal cancer, oesophageal cancer, pancreatic cancer, biliary cancer, prostate cancer and multiple cancer types. Conclusion: The prognostic value of systemic inflammation based prognostic scores has been confirmed in multiple trials and should be incorporated into future prospective randomised clinical trials.

Item Type:Articles
Additional Information:This research is funded by Glasgow University Clinical Research Fund.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Horgan, Professor Paul and Dolan, Dr Ross and McMillan, Professor Donald and Laird, Dr Barry
Authors: Dolan, R. D., Laird, B., Horgan, P. G., and McMillan, D. C.
College/School:College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Journal Name:Critical Reviews in Oncology/Hematology
Publisher:Elsevier
ISSN:1040-8428
ISSN (Online):1879-0461
Published Online:04 October 2018
Copyright Holders:Copyright © 2018 Elsevier
First Published:First published in Critical Reviews in Oncology/Hematology 132:130-137
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record